Clinical trial
Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab
NCT00858039 is registered in ClinicalTrials.gov with Royal Prince Alfred Hospital, Sydney, Australia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prediction of Cardiotoxicity Using Serum N-terminal Pro-B-type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab
- Lead sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- June 30, 2014
- Enrollment
- 220 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.